1. Home
  2. AGIO vs CXW Comparison

AGIO vs CXW Comparison

Compare AGIO & CXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.25

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo CoreCivic Inc.

CXW

CoreCivic Inc.

HOLD

Current Price

$19.61

Market Cap

2.1B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
CXW
Founded
2007
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2013
2001

Fundamental Metrics

Financial Performance
Metric
AGIO
CXW
Price
$27.25
$19.61
Analyst Decision
Buy
Strong Buy
Analyst Count
8
3
Target Price
$38.88
$32.00
AVG Volume (30 Days)
1.3M
603.7K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.19
EPS
N/A
1.08
Revenue
$43,011,000.00
$2,211,182,000.00
Revenue This Year
$76.75
$17.13
Revenue Next Year
$170.73
$5.64
P/E Ratio
N/A
$18.68
Revenue Growth
N/A
12.72
52 Week Low
$22.24
$15.74
52 Week High
$46.00
$23.54

Technical Indicators

Market Signals
Indicator
AGIO
CXW
Relative Strength Index (RSI) 43.00 42.61
Support Level $26.03 $19.27
Resistance Level $29.69 $19.61
Average True Range (ATR) 1.36 0.51
MACD -0.19 -0.11
Stochastic Oscillator 25.72 4.14

Price Performance

Historical Comparison
AGIO
CXW

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About CXW CoreCivic Inc.

CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.

Share on Social Networks: